{"analyses":[{"ciLowerLimit":"28.4","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"49.6","estimateComment":"Stratified Mantel-Haenszel with stratification factors based on IRT","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","pValueComment":"Stratified by tumor location (lower limb/all other) and region (U.S./non-U.S.) based on Interactive Response Technology (IRT).","paramType":"Difference in ORR","paramValue":"39.0","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.2","upperLimit":"51.1","value":"39.8"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"8.8","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"ORR was assessed by blinded independent radiologic review (IRR) using RECIST Version 1.1. ORR was defined as the percentage of participants who achieved either complete response (CR) or partial response (PR).\n\n* CR: Disappearance of all target lesions. Any pathological lymph nodes must be \\<10 millimeter (mm) in short axis. Non-nodal targets must be absent.\n* PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 30 mg BIW vimseltinib for 24 weeks.","id":"OG000","title":"Vimseltinib"},{"description":"Participants received matching placebo BIW for 24 weeks.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"The ITT Set consisted of participants who were randomized to a study treatment regimen.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 25 (Cycle 7, Day 1)","title":"Objective Response Rate (ORR) at Week 25 Per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1","type":"PRIMARY","unitOfMeasure":"percentage of participants with CR or PR"}